256 related articles for article (PubMed ID: 31533850)
21. The essential drugs concept is needed now more than ever.
Smith MK; Tickell S
Trans R Soc Trop Med Hyg; 2003; 97(1):2-5. PubMed ID: 12886792
[TBL] [Abstract][Full Text] [Related]
22. Rare essentials: drugs for rare diseases as essential medicines.
Stolk P; Willemen MJ; Leufkens HG
Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
[TBL] [Abstract][Full Text] [Related]
23. In which developing countries are patents on essential medicines being filed?
Beall RF; Blanchet R; Attaran A
Global Health; 2017 Jun; 13(1):38. PubMed ID: 28651631
[TBL] [Abstract][Full Text] [Related]
24. Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.
Jeličić Kadić A; Žanić M; Škaričić N; Marušić A
PLoS One; 2014; 9(10):e111474. PubMed ID: 25337860
[TBL] [Abstract][Full Text] [Related]
25. Trade, TRIPS, and pharmaceuticals.
Smith RD; Correa C; Oh C
Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
[TBL] [Abstract][Full Text] [Related]
26. Changing global essential medicines norms to improve access to AIDS treatment: lessons from Brazil.
Nunn A; Fonseca ED; Gruskin S
Glob Public Health; 2009; 4(2):131-49. PubMed ID: 19333805
[TBL] [Abstract][Full Text] [Related]
27. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
Babar ZU; Lessing C; Mace C; Bissell K
Pharmacoeconomics; 2013 Nov; 31(11):1063-82. PubMed ID: 24127259
[TBL] [Abstract][Full Text] [Related]
28. Access to essential medicines: a Hobbesian social contract approach.
Ashcroft RE
Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
[TBL] [Abstract][Full Text] [Related]
29. Canada and access to medicines in developing countries: intellectual property rights first.
Lexchin J
Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
[TBL] [Abstract][Full Text] [Related]
30. Access to medicines, market failure and market intervention: a tale of two regimes.
Williams OD
Glob Public Health; 2012; 7 Suppl 2():S127-43. PubMed ID: 23039022
[TBL] [Abstract][Full Text] [Related]
31. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
Cohen-Kohler JC; Forman L; Lipkus N
Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
[TBL] [Abstract][Full Text] [Related]
32. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries.
Mendis S; Fukino K; Cameron A; Laing R; Filipe A; Khatib O; Leowski J; Ewen M
Bull World Health Organ; 2007 Apr; 85(4):279-88. PubMed ID: 17546309
[TBL] [Abstract][Full Text] [Related]
33. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.
Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM
Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634
[TBL] [Abstract][Full Text] [Related]
34. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand.
Kuek V; Phillips K; Kohler JC
Glob Public Health; 2011; 6(2):111-24. PubMed ID: 20234967
[TBL] [Abstract][Full Text] [Related]
35. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines.
Faunce TA
Monash Bioeth Rev; 2005 Jul; 24(3):10-9. PubMed ID: 16302317
[TBL] [Abstract][Full Text] [Related]
36. Essential drugs in the new international economic environment.
Velásquez G; Boulet P
Bull World Health Organ; 1999; 77(3):288-92. PubMed ID: 10212525
[TBL] [Abstract][Full Text] [Related]
37. Global trade and health: key linkages and future challenges.
Bettcher DW; Yach D; Guindon GE
Bull World Health Organ; 2000; 78(4):521-34. PubMed ID: 10885181
[TBL] [Abstract][Full Text] [Related]
38. Anticancer medicines in Pakistan: An analysis of essential medicines lists.
Shukar S; Anjum R; Zhang J; Babar ZU; Mobeen I; Yang C
J Oncol Pharm Pract; 2024 Jan; 30(1):46-54. PubMed ID: 37006130
[TBL] [Abstract][Full Text] [Related]
39. Patents and access to essential drugs.
Loff B
Trans R Soc Trop Med Hyg; 2003; 97(1):6-9. PubMed ID: 12886793
[TBL] [Abstract][Full Text] [Related]
40. Essential medicines are more available than other medicines around the globe.
Bazargani YT; Ewen M; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
PLoS One; 2014; 9(2):e87576. PubMed ID: 24533058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
